Reuters logo
BRIEF-Astrazeneca says U.S. FDA accepts supplemental biologics license application for imfinzi
2017年10月17日 / 中午11点33分 / 1 个月前

BRIEF-Astrazeneca says U.S. FDA accepts supplemental biologics license application for imfinzi

Oct 17 (Reuters) - Astrazeneca Plc

* U.S. FDA accepts supplemental biologics license application for imfinzi (durvalumab) in locally advanced, unresectable non-small cell lung cancer

* Astrazeneca Plc - ‍imfinzi granted priority review​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below